Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENCANA CORPECA · Entity 153444 | Director | November 01, 2019 | November 01, 2019 |
| Faeth Therapeutics, Inc.SNSE · Entity 5029 | Director | May 21, 2025 | May 23, 2025 |
| Ovintiv Inc.OVV · Entity 3288 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENCANA CORP
Report date November 01, 2019 · Filed November 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 258,657 |
Reported balance
After 2019-11-01 transaction · row 1
1 source rowRow 1 · 2019-11-01 · Purchase · Acquired 62,500 · Balance 258,657 |
Faeth Therapeutics, Inc.
Report date May 21, 2025 · Filed May 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.32 · Expires 2035-05-20 | Direct | 19,000 |
Reported balance
After 2025-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-21 · Grant · Acquired 19,000 · Balance 19,000 F1: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.
Ovintiv Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 103,842 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Exercise / conversion · Acquired 3,510 · Balance 103,842 F3: Represents the settlement upon vesting of RSUs. F4: RSUs convert into Ovintiv common stock on a one-for-one basis. |
| Restricted Share UnitSEC Table II · derivative / convertible security · Expires 2026-05-21 | Direct | 3,510 |
Reported balance
After 2026-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-21 · Grant · Acquired 3,510 · Balance 3,510 F1: Each Restricted Share Unit ("RSU") is the economic equivalent of one share of common stock of Ovintiv Inc. ("Ovintiv") and yields dividend equivalent RSUs. Vesting and exercise will occur in accordance with the Omnibus Incentive Plan and the applicable grant agreement and on the same schedule as the underlying RSUs. |
| Restricted Share UnitSEC Table II · derivative / convertible security · Expires 2026-05-21 | Direct | 0 |
Reported balance
After 2026-05-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-21 · Exercise / conversion · Disposed 3,510 · Balance 0 F2: Each RSU is the economic equivalent of one share of Ovintiv common stock and yields dividend equivalent RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit ("RSU") is the economic equivalent of one share of common stock of Ovintiv Inc. ("Ovintiv") and yields dividend equivalent RSUs. Vesting and exercise will occur in accordance with the Omnibus Incentive Plan and the applicable grant agreement and on the same schedule as the underlying RSUs.
F2: Each RSU is the economic equivalent of one share of Ovintiv common stock and yields dividend equivalent RSUs.
F3: Represents the settlement upon vesting of RSUs.
F4: RSUs convert into Ovintiv common stock on a one-for-one basis.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NEWFIELD EXPLORATION CO /DE/
Report date February 13, 2019 · Filed February 14, 2019
Section 16 reporting ended · disclosed 2019-02-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| common stockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-02-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-02-13 · Disposition to issuer · Disposed 66,447 · Balance 6,968 F1: On February 13, 2019, pursuant to the Agreement and Plan of Merger dated as of October 31, 2018 (Merger Agreement), by and among Encana Corporation (Encana), Neapolitan Merger Corp. (Merger Sub), and Newfield Exploration Company (Newfield), Merger Sub merged with and into Newfield (the Merger) with Newfield surviving the Merger as a wholly-owned subsidiary of Encana. Pursuant to the Merger Agreement, upon consummation of the transactions contemplated therein, each share of Newfield common stock issued and outstanding was converted into the right to receive 2.6719 Encana common shares. Row 2 · 2019-02-13 · Disposition to issuer · Disposed 6,968 · Balance 0 F2: Pursuant to the Merger Agreement, upon consummation of the transactions contemplated therein, all outstanding Newfield restricted stock awards (RSAs) were cancelled and each holder of RSAs was entitled to receive, on a fully-vested basis for each such RSA, the merger consideration, as described in the Merger Agreement and in note (1) above. There was no purchase price. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 13, 2019, pursuant to the Agreement and Plan of Merger dated as of October 31, 2018 (Merger Agreement), by and among Encana Corporation (Encana), Neapolitan Merger Corp. (Merger Sub), and Newfield Exploration Company (Newfield), Merger Sub merged with and into Newfield (the Merger) with Newfield surviving the Merger as a wholly-owned subsidiary of Encana. Pursuant to the Merger Agreement, upon consummation of the transactions contemplated therein, each share of Newfield common stock issued and outstanding was converted into the right to receive 2.6719 Encana common shares.
F2: Pursuant to the Merger Agreement, upon consummation of the transactions contemplated therein, all outstanding Newfield restricted stock awards (RSAs) were cancelled and each holder of RSAs was entitled to receive, on a fully-vested basis for each such RSA, the merger consideration, as described in the Merger Agreement and in note (1) above. There was no purchase price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2021 Filed Feb 10, 2021 23:47 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | ConversionCommon Stock | 301,769 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009414 · doc4.xml · nonDerivative · entry 1 RICKS THOMAS G · CIK 0001013023 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 301,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The total represents shares received upon conversion of shares of Series AA Preferred Stock and Series BB Preferred Stock. F2 · price: Each share of the Series AA Preferred Stock and Series BB Preferred Stock converted to 0.0208333 shares of the Issuer's common stock, effective immediately prior to the closing of the Issuer's initial public offering of its common stock. The Series AA Preferred Stock and Series BB Preferred Stock had no expiration date. F3 · ownership.nature: These shares are held by the Ricks Family Trust. Thomas Ricks is a trustee of the Ricks Family Trust and accordingly may be deemed to have voting and dispositive power with respect to the shares held by Ricks Family Trust. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:43 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 16,666 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008099 · doc4.xml · derivative · entry 1 RICKS THOMAS G · CIK 0001013023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,666 Underlying: Common Stock · 16,666 shares Expires 2031-02-02 F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the options granted shall vest and become exercisable each month following February 3, 2021, the Vesting Commencement Date, over three years such that the options shall be 100% vested on the third anniversary of the Vesting Commencement Date, subject to the grantee's Continuous Service (as defined in the 2021 Equity Incentive Plan) through each such vesting date. Read SEC document |
| March 18, 2020 Filed Mar 18, 2020 20:37 UTC | Ovintiv Inc. OVV · Entity 3288 | PurchaseCommon Stock | 50,000 | $2.15 | $107,500.00 |
DisclosureSEC source: 0001667731-20-000172 · ownership.xml · nonDerivative · entry 1 RICKS THOMAS G · CIK 0001013023 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Ricks Family Trust Disclosed balance after: 155,500 Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 18:04 UTC | Ovintiv Inc. OVV · Entity 3288 | PurchaseCommon Stock | 40,000 | $2.55 | $102,076.00 |
DisclosureSEC source: 0001667731-20-000159 · rickspur200309.xml · nonDerivative · entry 2 RICKS THOMAS G · CIK 0001013023 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Ricks Family Trust Disclosed balance after: 105,500 Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 18:04 UTC | Ovintiv Inc. OVV · Entity 3288 | PurchaseCommon Stock | 25,000 | $4.06 | $101,375.00 |
DisclosureSEC source: 0001667731-20-000159 · rickspur200309.xml · nonDerivative · entry 1 RICKS THOMAS G · CIK 0001013023 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Ricks Family Trust Disclosed balance after: 65,500 Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 21:37 UTC | Ovintiv Inc. OVV · Entity 3288 | GrantRights (Director Restricted Stock Unit) · Derivative | 13,309 | $0.00 | $0.00 |
DisclosureSEC source: 0001667731-20-000099 · ricksrsu2020.xml · derivative · entry 1 RICKS THOMAS G · CIK 0001013023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,091 Underlying: Common Stock · 13,309 shares Expires not disclosed F2 · derivative.exercise_price: Each Director Restricted Stock Unit (each, "RSU") is the economic equivalent of one share of common stock of Ovintiv Inc. and attracts dividend equivalent RSUs. The RSUs vest immediately and settle on the earlier of February 28, 2023 or retirement from the Board, subject to the terms and conditions of the Omnibus Incentive Plan and applicable grant agreement. F2 · derivative.expiration_date: Each Director Restricted Stock Unit (each, "RSU") is the economic equivalent of one share of common stock of Ovintiv Inc. and attracts dividend equivalent RSUs. The RSUs vest immediately and settle on the earlier of February 28, 2023 or retirement from the Board, subject to the terms and conditions of the Omnibus Incentive Plan and applicable grant agreement. F1 · derivative.underlying: Pursuant to Rule 12g-3(a) under the Exchange Act, Ovintiv Inc. (Ovintiv) is the successor issuer to Encana Corporation ("Encana"). Read SEC document |
| February 27, 2020 Filed Feb 27, 2020 20:01 UTC | Ovintiv Inc. OVV · Entity 3288 | PurchaseCommon Stock | 25,000 | $10.71 | $267,652.50 |
DisclosureSEC source: 0001667731-20-000052 · ricks200227.xml · nonDerivative · entry 1 RICKS THOMAS G · CIK 0001013023 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Ricks Family Trust Disclosed balance after: 40,500 Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 23:14 UTC | Ovintiv Inc. OVV · Entity 3288 | PurchaseCommon Stock | 15,500 | $15.87 | $245,985.00 |
DisclosureSEC source: 0001667731-20-000037 · ricks200224.xml · nonDerivative · entry 1 RICKS THOMAS G · CIK 0001013023 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Ricks Family Trust Disclosed balance after: 15,500 F1 · security: Pursuant to Rule 12g-3(a) under the Exchange Act, Ovintiv is the successor issuer to Encana Corporation ("Encana"). Read SEC document |
| November 01, 2019 Filed Nov 1, 2019 18:24 UTC | ENCANA CORP ECA · Entity 153444 | PurchaseCommon Shares | 62,500 | $3.96 | $247,493.75 |
DisclosureSEC source: 0001667731-19-000289 · ricks191101.xml · nonDerivative · entry 1 RICKS THOMAS G · CIK 0001013023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,657 Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 15:49 UTC | ENCANA CORP ECA · Entity 153444 | GrantRights (Director Restricted Share Unit) · Derivative | 23,569 | $0.00 | $0.00 |
DisclosureSEC source: 0001667731-19-000064 · ricks8mar19.xml · derivative · entry 1 RICKS THOMAS G · CIK 0001013023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,569 Underlying: Common Shares · 23,569 shares Expires not disclosed F1 · derivative.exercise_price: Each Director Restricted Share Unit (each, "RSU") is the economic equivalent of one common share of Encana Corporation and attracts dividend equivalent RSUs. The RSUs vest immediately and settle on the earlier of March 8, 2022 or retirement from the Board, subject to the terms and conditions of the Omnibus Incentive Plan of Encana Corporation and applicable grant agreement. F1 · derivative.exercise_date: Each Director Restricted Share Unit (each, "RSU") is the economic equivalent of one common share of Encana Corporation and attracts dividend equivalent RSUs. The RSUs vest immediately and settle on the earlier of March 8, 2022 or retirement from the Board, subject to the terms and conditions of the Omnibus Incentive Plan of Encana Corporation and applicable grant agreement. F1 · derivative.expiration_date: Each Director Restricted Share Unit (each, "RSU") is the economic equivalent of one common share of Encana Corporation and attracts dividend equivalent RSUs. The RSUs vest immediately and settle on the earlier of March 8, 2022 or retirement from the Board, subject to the terms and conditions of the Omnibus Incentive Plan of Encana Corporation and applicable grant agreement. Read SEC document |
| February 13, 2019 Filed Feb 14, 2019 19:49 UTC | NEWFIELD EXPLORATION CO /DE/ NFX · Entity 160274 | Disposition to issuercommon stock | 6,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001246360-19-000612 · form.xml · nonDerivative · entry 2 RICKS THOMAS G · CIK 0001013023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: Pursuant to the Merger Agreement, upon consummation of the transactions contemplated therein, all outstanding Newfield restricted stock awards (RSAs) were cancelled and each holder of RSAs was entitled to receive, on a fully-vested basis for each such RSA, the merger consideration, as described in the Merger Agreement and in note (1) above. There was no purchase price. Read SEC document |
| February 13, 2019 Filed Feb 14, 2019 19:49 UTC | NEWFIELD EXPLORATION CO /DE/ NFX · Entity 160274 | Disposition to issuercommon stock | 66,447 | $0.00 | $0.00 |
DisclosureSEC source: 0001246360-19-000612 · form.xml · nonDerivative · entry 1 RICKS THOMAS G · CIK 0001013023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,968 F1 · shares: On February 13, 2019, pursuant to the Agreement and Plan of Merger dated as of October 31, 2018 (Merger Agreement), by and among Encana Corporation (Encana), Neapolitan Merger Corp. (Merger Sub), and Newfield Exploration Company (Newfield), Merger Sub merged with and into Newfield (the Merger) with Newfield surviving the Merger as a wholly-owned subsidiary of Encana. Pursuant to the Merger Agreement, upon consummation of the transactions contemplated therein, each share of Newfield common stock issued and outstanding was converted into the right to receive 2.6719 Encana common shares. Read SEC document |
| May 15, 2018 Filed May 16, 2018 18:21 UTC | NEWFIELD EXPLORATION CO /DE/ NFX · Entity 160274 | Grantcommon stock | 6,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001246360-18-001557 · form.xml · nonDerivative · entry 1 RICKS THOMAS G · CIK 0001013023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,415 Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 18:00 UTC | NEWFIELD EXPLORATION CO /DE/ NFX · Entity 160274 | Purchasecommon stock | 8,250 | $23.78 | $196,160.25 |
DisclosureSEC source: 0001246360-18-000965 · form.xml · nonDerivative · entry 1 RICKS THOMAS G · CIK 0001013023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,447 F1 · shares: Reflects the purchase of an aggregate of 8,250 shares of common stock on March 1, 2018 at the weighted average sale price of $23.7770. The prices for these purchases range from $23.7769 to $23.7775. The filer undertakes to provide, upon request by the Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 16, 2017 Filed May 18, 2017 17:49 UTC | NEWFIELD EXPLORATION CO /DE/ NFX · Entity 160274 | Grantcommon stock | 5,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001246360-17-001922 · form.xml · nonDerivative · entry 1 RICKS THOMAS G · CIK 0001013023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,197 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.